有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Habekacin;Arbekacin;Habekacin
Chemical Name 1-N-[(S)-4-Amino-2-hydroxybutyryl]dibekacin;1-N-[(S)-4-Amino-2-hydroxybutyryl]-3,4-dideoxykanamycin B;O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1--4)-O-[2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl-(1--6)]-N-[(2S)-4-amino-2-hydroxybutyryl]-2-deoxy-L-streptamine
CAS 51025-85-5
Related CAS 75282-65-4 (carbonate(1:2) salt)
Formula C22H44N6O10
Structure
Formula Weight 552.63018
Stage 上市-1990
Company Meiji Seika (Originator)
Activity/Mechanism Antibiotics, ANTIINFECTIVE THERAPY, Aminoglycosides
Syn. Route 5
Route 1
the acylation of 3,4-dideoxykanamycin b (dibekacin) (i) with n-benzyloxycarbonyloxysuccinimide (ii) and zinc acetate in dmso gives 3,2,6-tri-n-benzyloxycarbonydibekacin (iii), which is then treated with the n-hydroxysuccinimide ester of 2-hydroxy-4-aminobutyric acid (iv) and finally deprotected by hydrogenation with h2 over pd/c in acidic water dioxane.
List of intermediates No.
(4-chlorophenyl)methanesulfonyl chloride (i)
(ii)
(iii)
(iv)
Reference 1:
    umezawa, h.; umezawa, s.; tsuchiya, t.; takagi, y.; jikihara, t. (microbial chemistry research foundation); production of a selectively protected n-acylated derivative of an aminoglycosidic antibiotic. be 0879925; de 2945010; fr 2441631; fr 2482109; gb 2036020; gb 2065123; jp 80164696; jp 8064598; us 4297485 .
Reference 2:
    serradell, m.n.; castaner, j.; blancafort, p.; habekacin. drugs fut 1983, 8, 5, 410.

Route 2
the acylation of 3,4-dideoxykanamycin b (dibekacin) (i) with benzyloxycarbonyl chloride in water gives 6-n-benzyloxycarbonyldibekacin (v), which is then acylated with (iv) as before and deprotected by hydrogenolysis with h2 over pd/c in water - acetic acid.
List of intermediates No.
[5-[3-benzoyl-2,4-dioxo-5-vinyl-3,4-dihydro-1(2h)-pyrimidinyl]-3-(benzoyloxy)tetrahydro-2-furanyl]methyl benzoate
(4-chlorophenyl)methanesulfonyl chloride (i)
(iv)
(v)
Reference 1:
    umezawa, h.; umezawa, s.; maeda, k.; tsuchiya, o.; kondo, s.; fukatsu, s. (microbial chemistry research foundation); 1-n-[(s)-alpha-hydroxy-omega-aminoacyl]. de 2530169; fr 2201875; gb 1426908; jp 7462442; jp 7480039; jp 7494648; jp 7733629; jp 8003357; us 4001208; us 4107424 .
Reference 2:
    serradell, m.n.; castaner, j.; blancafort, p.; habekacin. drugs fut 1983, 8, 5, 410.

Route 3
the acylation of 3,2,6-tri-n-benzyloxycarbonydibekacin (iii) with ethyl trifluoroacetate and k2co3 gives 3,2,6-tri-n-benzyloxycarbonyl-3-trifluoroacetyldibekacin (vi), which is acylated again with (iv) yielding the protected habekacin (vii). finally, this compound is deprotected by hydrolysis with ammonia in aqueous thf, followed by hydrogenolysis with h2 over pd/c.
List of intermediates No.
(4-chlorophenyl)methanesulfonyl chloride (i)
(ii)
(iii)
(iv)
5-iodo-3-thiophenecarbaldehyde (vi)
(5-iodo-3-thienyl)methanol (vii)
Reference 1:
    tsuchiya, t.; takagi, y.; umezawa, s.; 1-n-acylation of aminocyclitol antibiotics via zinc chelation and regiospecific n-trifluoroacetylation. tetrahedron lett 1979, 51, 4951-54.
Reference 2:
    serradell, m.n.; castaner, j.; blancafort, p.; habekacin. drugs fut 1983, 8, 5, 410.

Route 4
the acylation of 3,4-dideoxykanamycin b (dibekacin) (i) with tert-butyl-s-(4,6-dimethylpyrimid-2-yl)thiocarbonate (viii) by means of triethylamine in isopropanol gives 3,2,6-tri-n-tert-butyloxycarbonyldibekacin (ix), which is acylated again with 4-benzyloxycarbonylamino-2-hydroxybutyric acid n-hydroxysuccinimide ester (x) in the yielding the protected habekacin (xi). finally, this compound is deprotected by a treatment with trifluoroacetic acid, followed by hydrogenolysis with h2 over pd/c in methanol - acetic acid.
List of intermediates No.
(4-chlorophenyl)methanesulfonyl chloride (i)
(viii)
(ix)
(x)
(xi)
Reference 1:
    umezawa, h.; kondo, s. (microbial chemistry research foundation); process for the preparation of 1-n-isoseryl- or 1-n-(l-4-amino-2-hydroxybutyryl)-3,4-dideoxykanamycin b and intermediates thereof. de 2950020; fr 2444046; gb 2038329; gb 2072676; gb 2072677; jp 55081897; us 4268664 .
Reference 2:
    serradell, m.n.; castaner, j.; blancafort, p.; habekacin. drugs fut 1983, 8, 5, 410.

Route 5
the acylation of 3,4-dideoxy-3,4-didehydrokanamycin b (xii) with tert-butyl-s-(4,6-dimethylpyrimid-2-yl)thiocarbonate (viii) as before gives 3,2,6-tri-n-butoxycarbonyl-3,4-dideoxy-3,4-didehydrokanamycin b (xiii), which is acylated again with (x) as before yielding the fully protected 3,4-didehydrohabekacin (xiv). partial deprotection of (xiv) with trifluoroacetic acid affords 1-n-(4-benzyloxycarbonylamino-2-hydroxybutyryl)-3,4-dideoxy-3,4-didehydrokanamycin b (xv), which is finally debenzylated and reduced by a treatment with h2 over pto2 in aqueous acetic acid.
List of intermediates No.
(viii)
(x)
(xii)
(xiii)
(5r,6s)-6-[4-(propylsulfonyl)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane; 4-[(5r,6s)-1-azabicyclo[3.2.1]oct-6-yl]-1,2,5-thiadiazol-3-yl propyl sulfone (xiv)
4-[(5r,6s)-1-azabicyclo[3.2.1]oct-6-yl]-1,2,5-thiadiazole-3-thiol; 4-[(5r,6s)-1-azabicyclo[3.2.1]oct-6-yl]-1,2,5-thiadiazol-3-ylhydrosulfide (xv)
Reference 1:
    serradell, m.n.; castaner, j.; blancafort, p.; habekacin. drugs fut 1983, 8, 5, 410.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名阿贝卡星;英文名Habekacin;Arbekacin;Habekacin;CAS[51025-85-5]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
科迪华旗下喹禾灵除草剂产品线被
国光股份募集资金投资项目变更实
杨森在欧洲申请优特克单抗用于治
BMS 白血病药物组合 Spr
辉瑞与默克宣布终止癌症药物 B
增加至7000万!国光股份子公
hVIVO 启动通用流感疫苗
民族骄傲!氰烯菌酯再获国家科学
农药领域的行政许可事项相互之间
暂停?不存在的!2019年将全
诺华镰状细胞病药物 Criza
全力整改!广安利尔草铵膦生产线
葛兰素史克积极寻求处于研发初期
多个植保农药类项目拟提名201
市场行情走低,库存持续消化
EMA 批准氟替卡松用于儿童哮
安进骨质疏松症药物 Eveni
葛兰素史克时隔 4 年拟重返肿
河南地区醋酸价格
山东地区醋酸价格下调
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明